Toronto Study Uncovers 81 Genes Behind TNBC

Toronto researchers have identified 81 previously unrecognised genes that drive basal-like breast cancer (BLBC), also known as triple-negative breast cancer, using a new CRISPR-based gene-editing tool developed in-house. Published in Nature on 8 July 2026, the discovery expands understanding of the most aggressive and hardest-to-treat form of the disease, one of the few breast cancer subtypes where precision therapies remain largely unavailable.

The study was led by Dr Daniel Schramek at the Lunenfeld-Tanenbaum Research Institute and Dr Khalid Al-Zahrani, now at the University of Toronto. The team built on prior work adapting CRISPR for use in the mouse mammary gland, allowing thousands of genes to be tested simultaneously in a single animal. Al-Zahrani, Schramek and Dr Jeff Wrana then developed CRISPR-KOALA, which gives the platform the ability to silence and activate genes at the same time, letting researchers screen more than 3,700 genes on chromosomes commonly rearranged in BLBC.

Of the 81 new BLBC driver genes identified, 90% were entirely undetected in standard cell culture experiments, highlighting how in vivo screening captures biology that only emerges within a real tumour environment. PLGRKT stood out as a particularly potent driver, helping cancer cells survive in low-oxygen tumour cores by shifting to a different metabolic process, and was flagged as a compelling candidate for targeted therapy. Triple-negative breast cancer disproportionately affects younger women of colour and carries some of the worst outcomes across the breast cancer category, with tumours lacking the three receptor types clinicians use to target treatment in other subtypes.

The commercial signal cuts both ways. On the drug discovery side, 81 new potential target genes plus PLGRKT as a particularly promising candidate opens a substantial pipeline opportunity for oncology developers focused on TNBC. On the platform side, CRISPR-KOALA joins a growing category of in-vivo screening tools that could reshape how early-stage biotechs and pharma R&D teams prioritise oncology targets across the sector.

For the latest updates and in-depth insights into the world of Life Science, including breakthrough treatments, industry trends, and regulatory news, contact Adam Tiberius today!